MLS Medical Solutn

    For further information, please contact:

                                                          Medical Solutions plc
                                                                    Dr Nick Ash
                                                              Managing Director
                                                             Tel: 0115 973 9010
                                                    www.medical-solutions.co.uk
                                                                               
                                                 Bishopsgate Communications Ltd
                                                       Nick Rome / Sophie Davis
                                                             Tel: 0207 562 3350
                                              www.bishopsgatecommunications.com

7 June 2007

                             Medical Solutions plc                             

                     (`Medical Solutions' or the `Group')                      

                       Annual General Meeting Statement                        

Laurie Turnbull, Chairman of Medical Solutions, will be making the following
statement at the 2007 Annual General Meeting today:

General Statement

This is my first AGM as Chairman of Medical Solutions and I am delighted to
report that a great deal of progress has been made both in the year and since
the financial year end, and that the Group is now significantly stronger, both
financially and operationally, than it has ever been. November 2006 saw the
completed disposal of Dubai operations, which now enables the full focus of the
Directors and senior management to be targeted towards the achievement of the
key strategic aims I outlined to shareholders in March of this year.

An important step in achieving our aim to be a leading provider of healthcare
and diagnostic services was announced this morning, with the proposed
acquisition of Geneservice Limited. Geneservice is a profitable, cash
generative and expanding company offering a comprehensive portfolio of genomic
products and services. The acquisition benefits the Group by providing an
enhanced service offering to include DNA and RNA based technologies which are
in demand from the pharmaceutical and biotechnology industries. We also aim to
realise cost benefits by the consolidation of certain operations to our
reference laboratories in Nottingham.

Trading Update

The Group's results for the year ended 31 December 2006 demonstrate that
significant progress has been made in the continuing operations of the Group.
The Board remains committed to the achievement of profitability and cash
generation through organic growth of the existing business, in combination with
selected acquisitions.

Pathology Services

In the Diagnostic Pathology business, the continued growth in HER2 testing
volumes and a full year's benefit from the consolidation of operations onto a
single site in Nottingham, coupled with the ongoing strong cost control in
other areas, has led to a significantly improved operating performance for this
part of the business.

The Board has targeted the expansion of its offering in Diagnostic Pathology
which has seen the introduction of tailored packages of diagnostic and
theranostic tests, the first of these being the Medical Solutions Breast Cancer
Decision Making Tool.

The restructuring of Drug Development Services and ongoing focus on the
underlying costs have continued to realise benefits for this area of the
business during the year. We have refocused our sales and marketing activity
resulting in an increased conversion from sales to project proposals during the
second half of the year, with a notable increased interest in the use of
biomarkers in this sector.

Liquid Based Cytology ("LBC")

Cytology has become a genuine success story for Medical Solutions with the
division exceeding original expectations in respect of market share, and is now
expected to achieve 47% of the market for LBC in England and Wales. We are at
the forefront of cervical cancer screening in the UK, supplying LBC equipment,
consumables and technical support to Hospital Trusts throughout the UK. The
next stage of our Cytology strategy is to accelerate the introduction of
automated cytology screening and we have initiated a number of clinical trials
to support this strategy.

Number One Health Group Limited

On 3 April 2007 Medical Solutions acquired a 40% shareholding in the private
healthcare provider Number One Health and this investment provides a channel
through which Medical Solutions can market its existing portfolio of diagnostic
tests directly to the public. Additionally, diagnostic testing that is
currently outsourced by Number One Health can be performed at Medical
Solutions' reference laboratories in Nottingham.

Geneservice Limited

Medical Solutions announced today that it has conditionally agreed to acquire
the entire issued share capital of Geneservice Limited for a total
consideration of �3.86 million payable in cash and loan notes. Geneservice's
expertise in genomic based products and services will greatly enhance the
Group's diagnostic offering and be a valuable addition to our growing portfolio
of diagnostic services

The Board believes that satisfactory progress has been made towards the
achievement of our short-term aims and looks forward to updating shareholders
further following the release of our interim results for the six months ended
30 June 2007.

Notes to Editors

Medical Solutions plc (LSE: MLS)

Medical Solutions is a fully listed UK based diagnostics and healthcare
business specialising in the provision of diagnostic pathology and cytology
services and products to the healthcare, pharmaceutical and biotechnology
sectors. It has internationally recognised expertise in histopathology with
advanced technology in image analysis, high throughput quantitative protein
expression and biomarker determination. For more information about Medical
Solutions please visit www.medical-solutions.co.uk



END

Medical Solutions (LSE:MLS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Medical Solutions (LSE:MLS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024